Generic Approved for Forteo
On Nov. 16, 2023, Teva Pharmaceuticals’ teriparatide injection, a generic to Eli Lilly and Company’s Forteo®, was approved by the U.S. Food and Drug Administration (FDA). The once-daily parathyroid hormone (PTH 1-34) is used for treating individuals who have osteoporosis, who have a high risk of experiencing a fracture, and who already have tried other drugs for osteoporosis. Specifically, it is indicated for women who have postmenopausal osteoporosis, men who have primary or hypogonadal osteoporosis, and patients of either gender who have osteoporosis associated with taking long-term glucocorticoid therapy. Doses are given subcutaneously (SC) through a self-injector device that contains enough teriparatide for 28 days. Using teriparatide should be re-evaluated after two years. Teva’s generic should be released in the U.S. within the coming weeks. Estimated sales of Forteo were $609 million for the 12-month period that ended on July 31, 2023.